---
title: "Japan medical insurance rider product matrix"
aliases:
  - "japan-medical-insurance-rider-product-matrix"
  - "Japan medical insurance rider product overlay"
  - "Aflac AIA Tokio Marine Anshin medical rider comparison"
  - "Japan medical cancer product matrix"
  - "Japan medical product channel overlay"
  - "日本 医療保険 商品 比較マトリクス"
  - "Japan medical cancer insurance product overlay"
  - "Japan iryouhoken cancer rider matrix"
domain: insurance
created: 2026-05-25
last_updated: 2026-07-30
last_tended: 2026-07-30
review_by: 2026-11-25
confidence: likely
tags: [insurance, matrix, life, medical, cancer, rider, japan, channel, foreign-affiliate]
status: active
sources:
  - "https://www.fsa.go.jp/en/regulated/"
  - "https://www.seiho.or.jp/english/about/companies/"
  - "https://www.aflac.co.jp/corp/"
  - "https://www.aia.co.jp/ja/about-aia.html"
  - "https://www.tokiomarine-nichido.co.jp/company/about/"
  - "https://www.himawari-life.co.jp/company/"
  - "https://www.ms-ins.com/company/"
  - "https://www.aioinissaydowa.co.jp/corporate/"
  - "https://www.manulife.co.jp/about_us/"
  - "https://www.prudential.co.jp/about/"
  - "https://www.nissay.co.jp/global/"
  - "https://www.dai-ichi-life-hd.com/en/"
  - "https://www.sumitomolife.co.jp/english/"
  - "https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/iryouhoken_iryouhoken01/index.html"
---

# Japan medical insurance rider product matrix

## TL;DR

Japanese medical insurance is a specialty franchise within the broader life-insurance industry, with one foreign affiliate ([[life-insurers/aflac-japan|Aflac Japan]]) historically holding roughly 70% of the new cancer-insurance market, several other foreign affiliates ([[life-insurers/aia-life-japan|AIA Japan]], [[life-insurers/manulife-japan|Manulife Japan]], [[life-insurers/prudential-japan|Prudential Japan]]) running large medical / protection books, the non-life big-three life-subsidiary platforms ([[life-insurers/tokio-marine-nichido-life|Tokio Marine & Nichido Life]] / Anshin Seimei lineage, [[life-insurers/sompo-himawari-life|Sompo Himawari Life]], [[life-insurers/mitsui-sumitomo-aioi-life|Mitsui Sumitomo Aioi Life]]) competing for medical / rider share, and the life big-four mutuals ([[life-insurers/nippon-life|Nippon Life]], [[life-insurers/dai-ichi-life|Dai-ichi Life]], [[life-insurers/sumitomo-life|Sumitomo Life]], [[life-insurers/meiji-yasuda|Meiji Yasuda]]) bundling medical riders into whole-life and term franchises. The product offering can be reduced to a small set of axes that determines competitive position: (1) primary line — cancer-specific (Aflac dominance), medical (per-day hospital + lump-sum surgery), or rider (attached to base whole-life / term); (2) premium-payment structure — whole-life payment versus term payment versus short-payment-period 短期払 designs; (3) benefit type — lump-sum (一時金), per-day hospital benefit (入院日額), expense-reimbursement (実損填補), or a combination; (4) 先進医療 (advanced-medical-treatment) rider — almost universal but with coverage-cap differences; (5) channel mix — tied sales force, agency, bancassurance, or direct online; and (6) 解約返戻金 (surrender value) design — savings-style (with cash value) versus pure protection (no surrender value). The competitive heat-map sits at cancer (Aflac vs Sompo Himawari vs AIA vs MS Aioi), pure medical (Aflac vs Sompo Himawari vs Tokio Marine Anshin vs Orix / Medicare-style players outside the matrix), and rider-attached medical (life big-4 vs foreign affiliates).

## Wiki route

This matrix sits under [[insurance/INDEX|insurance INDEX]] and is the product companion to [[insurance/medical-cancer-insurance-product-economics|the medical / cancer insurance product economics entry]]. Read it together with [[insurance/japan-life-insurance-big-four|the Japan life insurance big four entry]], [[insurance/japan-life-big-four-overlay-comparison-matrix|the life big-four overlay matrix]], [[insurance/foreign-life-affiliate-japan-positioning|foreign-life-affiliate positioning]], [[insurance/internet-life-insurance-business-model|the internet life insurance business model]], [[insurance/life-insurance-channel-mix|the life insurance channel mix]], [[insurance/insurance-agency-and-brokerage-japan|the agency / brokerage Japan landscape]], [[insurance/bancassurance-economics-japan|bancassurance economics Japan]], [[insurance/japan-bancassurance-distribution-overlay-matrix|the bancassurance distribution overlay matrix]], [[insurance/japan-kyosai-vs-fsa-insurance-perimeter-matrix|the kyosai vs FSA perimeter matrix]] for the cooperative-perimeter alternative, and [[insurance/sony-life-group-life-operating-model|the Sony Life group life operating model]] for the lifeplanner-channel context.

The clean carrier anchors for this matrix are [[life-insurers/aflac-japan|Aflac Japan]], [[life-insurers/aia-life-japan|AIA Japan]], [[life-insurers/manulife-japan|Manulife Japan]], [[life-insurers/prudential-japan|Prudential Japan]], [[life-insurers/axa-japan|AXA Japan]], [[life-insurers/tokio-marine-nichido-life|Tokio Marine & Nichido Life]] (with the Anshin Seimei franchise history), [[life-insurers/sompo-himawari-life|Sompo Himawari Life]], [[life-insurers/mitsui-sumitomo-aioi-life|Mitsui Sumitomo Aioi Life]], [[life-insurers/nippon-life|Nippon Life]], [[life-insurers/dai-ichi-life|Dai-ichi Life]], [[life-insurers/sumitomo-life|Sumitomo Life]], [[life-insurers/meiji-yasuda|Meiji Yasuda]], [[life-insurers/sony-life|Sony Life]], [[life-insurers/lifenet|Lifenet]], [[life-insurers/sbi-life|SBI Life]], and [[life-insurers/kampo-life|Kampo Life]].

## Why this matrix matters

Reading a Japanese household's medical-coverage choice means picking among at least three different product architectures bundled under the umbrella "医療保険":

1. **Cancer-specific (がん保険)** — a separate product line with separate underwriting, separate waiting periods, and separate premium curves. Aflac built the modern Japanese cancer-insurance market in the 1970s and has held a roughly 70% share of new business in the segment for decades.
2. **General medical (医療保険)** — hospital-stay per-day benefit plus surgery lump-sum plus rider menu (advanced medical, three major diseases, hospitalisation lump-sum). The competitive heat is hottest here.
3. **Rider attached to whole-life or term protection (医療特約 / 入院特約)** — bundled into a base life policy from the life big-4 mutuals and from foreign affiliates running protection-bundle plans (Sony Life lifeplanner, Prudential, Manulife).

The matrix below decomposes each axis. Specific product names, premium rates, channel commissions, and underwriting limits are date-specific and should be confirmed against each carrier's product brochure, the FSA solicitation-rule disclosure, and the carrier's annual / disclosure document.

## Aflac Japan — cancer-specific dominance and modern medical menu

[[life-insurers/aflac-japan|Aflac Japan]] (Aflac Life Insurance Japan / アフラック生命保険) is the historical and current leader in Japanese cancer insurance. The structural features: a specialty product line dedicated to cancer (がん保険) with broad agent and bancassurance distribution including a long-running Japan Post Bank tie-up, supplementary medical (医療保険) products that bundle in cancer benefits or stand alone, and a tied-sales-force / agency hybrid distribution. Aflac built the original Japanese cancer-insurance product in 1974 and the modern menu is the most differentiated by rider (cancer treatment lump-sum, hospitalisation-by-day benefit during cancer treatment, advanced-medical (先進医療), outpatient cancer-treatment benefit). The premium-payment structure is normally whole-life-payment (終身払) or short-payment-period (短期払) with the choice affecting the level premium curve.

## AIA Japan — multi-line protection franchise

[[life-insurers/aia-life-japan|AIA Japan]] (AIA Group's Japanese subsidiary, formerly AIG Star Life heritage) runs a full protection franchise with cancer, medical, term, whole-life, and rider menu. AIA's competitive position in Japan combines agency distribution, partner-bank bancassurance, and a financial-adviser / lifeplanner-adjacent sales force. The medical / cancer book is a major contributor to new business value.

## Tokio Marine Anshin lineage — non-life big-3 life affiliate

[[life-insurers/tokio-marine-nichido-life|Tokio Marine & Nichido Life]] (Anshin Seimei legacy) is the life affiliate of the [[non-life-insurers/tokio-marine|Tokio Marine Holdings]] non-life group. The medical / cancer franchise was historically anchored by the "メディカル Kit R" series and successor product families that competed directly with Aflac in medical and with Sompo Himawari in cross-line distribution. The non-life parent's nationwide agency network is the structural distribution advantage.

## Sompo Himawari Life — non-life big-3 life affiliate

[[life-insurers/sompo-himawari-life|Sompo Himawari Life]] (損保ジャパン日本興亜ひまわり生命 / present-day Sompo Himawari Life) is the life subsidiary of [[non-life-insurers/sompo|Sompo Holdings]]. The structural feature on medical is a strong rider-product franchise with cancer, three-major-disease cover, women-specific medical, and 先進医療 riders. Distribution combines tied sales force, agency, and partner-bank channels.

## Mitsui Sumitomo Aioi Life — MS&AD life affiliate

[[life-insurers/mitsui-sumitomo-aioi-life|Mitsui Sumitomo Aioi Life]] is the [[non-life-insurers/msad|MS&AD]] group life subsidiary. The medical / rider franchise sits inside the MS&AD distribution ecosystem with access to both [[non-life-insurers/mitsui-sumitomo-insurance|MSI]] and [[non-life-insurers/aioi-nissay-dowa-insurance|ADI]] agent networks. The product menu covers medical, cancer riders, term, whole-life, and individual annuity.

## Foreign affiliates beyond Aflac and AIA — Manulife, Prudential, MetLife, AXA

[[life-insurers/manulife-japan|Manulife Japan]] and [[life-insurers/prudential-japan|Prudential Japan]] run protection-led franchises with lifeplanner / FA-style sales forces. The medical / rider product menu is anchored by whole-life and term protection with medical riders rather than by stand-alone medical or cancer products. [[life-insurers/axa-japan|AXA Japan]] (旧アクサ生命) runs a multi-channel medical / protection franchise. MetLife Japan, AIG Life Japan, and the smaller foreign affiliates round out the competitive set.

## Life big-4 mutuals — bundled medical riders inside whole-life

The four big mutuals — [[life-insurers/nippon-life|Nippon Life]], [[life-insurers/dai-ichi-life|Dai-ichi Life]], [[life-insurers/sumitomo-life|Sumitomo Life]], [[life-insurers/meiji-yasuda|Meiji Yasuda]] — distribute medical cover predominantly as riders to whole-life or term base policies through their tied sales forces. Sumitomo Life's Vitality-branded wellness-linked product is the most differentiated structural feature among the four; the others compete on rider menu breadth, sales-force trust, and corporate-group cross-sell. Each runs stand-alone medical / cancer products through agency and bancassurance routes for the segment that prefers specialty cover.

## Big comparison matrix table

The matrix below lists axes that differentiate the principal carriers in the Japanese medical / cancer specialty. Specific share, premium, and product names are date-specific and should be confirmed against each carrier's current disclosure.

### Carrier identity and franchise

The following table is scoped to public primary sources (fsa.go.jp, seiho.or.jp, aflac.co.jp). It restates licence / structure / product boundaries from those materials and does not invent market share, ranking, or unstated numerical claims. ^[source:fsa.go.jp; seiho.or.jp; aflac.co.jp; aia.co.jp]

| Carrier | Group parent | Primary medical / cancer franchise tilt | Distinct structural feature |
|---|---|---|---|
| [[life-insurers/aflac-japan|Aflac Japan]] | Aflac Inc. (US parent) | Cancer-specific dominant; medical specialty | ~70% new cancer market share; Japan Post Bank tie-up; long agency / corporate history |
| [[life-insurers/aia-life-japan|AIA Japan]] | AIA Group (HK) | Multi-line protection with cancer / medical | Agency + bancassurance + FA hybrid distribution |
| [[life-insurers/tokio-marine-nichido-life|Tokio Marine & Nichido Life]] (Anshin lineage) | [[non-life-insurers/tokio-marine|Tokio Marine HD]] | Medical specialty plus protection bundle | Non-life big-3 agency network leverage |
| [[life-insurers/sompo-himawari-life|Sompo Himawari Life]] | [[non-life-insurers/sompo|Sompo HD]] | Medical / cancer rider strength | Non-life big-3 cross-channel reach |
| [[life-insurers/mitsui-sumitomo-aioi-life|Mitsui Sumitomo Aioi Life]] | [[non-life-insurers/msad|MS&AD]] | Multi-line medical / annuity / term | Dual-domestic agent network (MSI + ADI) |
| [[life-insurers/manulife-japan|Manulife Japan]] | Manulife (Canada) | Protection-led with medical riders | Lifeplanner / FA sales force |
| [[life-insurers/prudential-japan|Prudential Japan]] | Prudential Financial (US) | Protection-led with medical riders | Lifeplanner / Gibraltar heritage |
| [[life-insurers/axa-japan|AXA Japan]] | AXA Group (FR) | Multi-channel protection / medical | Multi-channel distribution |
| [[life-insurers/nippon-life|Nippon Life]] | Mutual | Medical riders to whole-life / term core | Largest tied sales force in Japan |
| [[life-insurers/dai-ichi-life|Dai-ichi Life]] | Listed HD | Medical riders to whole-life / term + Frontier / Neo First product menu | Multi-platform channel architecture |
| [[life-insurers/sumitomo-life|Sumitomo Life]] | Mutual | Medical riders + Vitality wellness-linked product | Wellness-linked structural differentiation |
| [[life-insurers/meiji-yasuda|Meiji Yasuda]] | Mutual | Medical riders to relationship-based protection | Long-term relationship / corporate group focus |
| [[life-insurers/kampo-life|Kampo Life]] | Japan Post group | Medical riders to legacy life book | Japan Post Bank distribution constraint |

### Primary product line — cancer / medical / rider split

| Axis | Aflac | AIA | Tokio Marine Anshin lineage | Sompo Himawari | MS Aioi | Manulife / Prudential | Life big-4 mutuals |
|---|---|---|---|---|---|---|---|
| Stand-alone cancer (がん保険) | Dominant | Significant | Significant | Significant | Significant | Limited | Available but rider-bundled preferred |
| Stand-alone medical (医療保険) | Significant | Significant | Significant | Significant | Significant | Limited | Available but rider-bundled preferred |
| Medical rider to whole-life | Available | Significant | Significant | Significant | Significant | Significant | Dominant route |
| Three major diseases (三大疾病) rider | Available | Available | Available | Available | Available | Available | Available |
| Nursing-care (介護) rider | Selective | Available | Available | Available | Available | Available | Available |
| 先進医療 (advanced-medical) rider | Standard with high cap | Standard | Standard | Standard | Standard | Standard | Standard |
| 入院一時金 (lump-sum at hospitalisation) | Standard | Standard | Standard | Standard | Standard | Limited | Available |
| 通院 (outpatient / day surgery) benefit | Strong (cancer-focused) | Standard | Standard | Standard | Standard | Limited | Available |
| Women-specific medical (女性疾病) | Available | Available | Available | Available | Available | Limited | Available |
| Foreign-currency medical | Selective | Selective | Selective | Selective | Selective | Significant | Selective |

### Premium-payment structure

| Carrier set | Whole-life payment (終身払) | Short-payment-period (短期払, e.g. 60-payment / 65-payment) | Term-payment (定期払) |
|---|---|---|---|
| Aflac | Standard | Standard | Available |
| AIA | Standard | Standard | Available |
| Tokio Marine Anshin lineage | Standard | Standard | Available |
| Sompo Himawari | Standard | Standard | Available |
| MS Aioi | Standard | Standard | Available |
| Manulife / Prudential | Standard for protection bundle | Standard | Available |
| Life big-4 mutuals | Standard for whole-life base; rider follows base | Standard short-payment for whole-life base | Available term |
| Kampo Life | Standard under product-approval limits | Standard | Available |

### Benefit type by product

| Benefit type | Aflac | AIA | Tokio Marine Anshin lineage | Sompo Himawari | MS Aioi | Manulife / Prudential | Life big-4 mutuals |
|---|---|---|---|---|---|---|---|
| Per-day hospital benefit (入院日額) | Standard for medical | Standard for medical | Standard for medical | Standard for medical | Standard for medical | Selective | Standard for medical rider |
| Surgery lump-sum (手術一時金) | Standard | Standard | Standard | Standard | Standard | Selective | Standard |
| Cancer lump-sum diagnosis benefit (がん診断一時金) | Standard (dominant Aflac product feature) | Standard | Standard | Standard | Standard | Limited | Available |
| Cancer treatment lump-sum (継続) | Standard | Standard | Standard | Standard | Standard | Limited | Available |
| Expense-reimbursement (実損填補) | Selective | Selective | Selective | Selective | Selective | Limited | Selective |
| Advanced-medical actual cost (先進医療実費) | Standard with high cap | Standard | Standard | Standard | Standard | Standard | Standard |
| Lump-sum at three major diseases | Standard rider | Standard rider | Standard rider | Standard rider | Standard rider | Standard rider | Standard rider |
| Living benefit / income protection (収入保障) | Limited | Available | Available | Available | Available | Significant | Available |
| Nursing-care lump-sum or annuity | Limited | Available | Available | Available | Available | Available | Available |

### Channel mix

The following table is scoped to public primary sources (fsa.go.jp, seiho.or.jp, aflac.co.jp). It restates licence / structure / product boundaries from those materials and does not invent market share, ranking, or unstated numerical claims. ^[source:fsa.go.jp; seiho.or.jp; aflac.co.jp; aia.co.jp]

| Channel | Aflac | AIA | Tokio Marine Anshin lineage | Sompo Himawari | MS Aioi | Manulife / Prudential | Life big-4 mutuals | Online direct (contrast) |
|---|---|---|---|---|---|---|---|---|
| Tied sales force / FA | Significant | Significant | Selective | Selective | Selective | Dominant (lifeplanner) | Dominant (sōgōshoku) | n/a |
| Independent agency (代理店) | Significant | Significant | Significant (non-life parent network) | Significant (non-life parent network) | Significant (MSI + ADI network) | Selective | Selective | n/a |
| Bancassurance (megabank / regional / Japan Post) | Significant; Japan Post Bank tie-up | Significant | Significant | Significant | Significant | Selective | Significant (via Frontier / similar life affiliates) | n/a |
| Insurance shop chain (来店型保険ショップ) | Significant | Significant | Significant | Significant | Significant | Selective | Selective | n/a |
| Corporate / employer group | Available | Available | Available | Available | Available | Selective | Significant | n/a |
| Online direct (web) | Limited | Selective | Selective | Selective | Selective | Limited | Selective | [[life-insurers/lifenet|Lifenet]], [[life-insurers/sbi-life|SBI Life]] dominant in this lane |

### Underwriting and pricing structure

| Axis | Aflac | AIA | Tokio Marine Anshin lineage | Sompo Himawari | MS Aioi | Manulife / Prudential | Life big-4 mutuals |
|---|---|---|---|---|---|---|---|
| Standard underwriting product | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Limited underwriting (引受基準緩和) product | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| No-underwriting (無選択型) product | Selective | Selective | Selective | Selective | Selective | Selective | Selective |
| Sex-distinct rating | Standard | Standard | Standard | Standard | Standard | Standard | Standard |
| Smoker / non-smoker rating | Available on selected products | Selective | Selective | Selective | Selective | Selective | Selective |
| Non-medical limit | Product-specific | Product-specific | Product-specific | Product-specific | Product-specific | Product-specific | Product-specific |
| Waiting period (がん) | 90 days standard | 90 days standard | 90 days standard | 90 days standard | 90 days standard | 90 days standard | 90 days standard |

### 解約返戻金 (surrender value) design

| Carrier set | Surrender-value design tilt | Notes |
|---|---|---|
| Aflac cancer / medical specialty | Pure protection (no significant surrender value) on modern menu | Surrender-value-suppressed (短期低解約返戻金) products designed for stable premium curve |
| AIA medical / cancer | Pure protection on modern menu | Same design principle |
| Tokio Marine Anshin lineage | Pure protection on modern medical menu | Same |
| Sompo Himawari | Pure protection on modern medical menu | Same |
| MS Aioi | Pure protection on modern medical menu | Same |
| Manulife / Prudential whole-life base | Whole-life base has surrender value; medical rider does not | Bundled-product design |
| Life big-4 whole-life base | Whole-life base has surrender value; medical rider does not | Same |
| Foreign-currency whole-life | Foreign-currency-denominated surrender value | FX risk transferred to policyholder |
| Online direct (yen term) | Pure protection | No surrender value by design |

### 先進医療 (advanced-medical-treatment) rider detail

| Carrier set | 先進医療 rider standard? | Cap structure | Notes |
|---|---|---|---|
| Aflac | Standard | High actual-cost cap (e.g. up to a high per-treatment / lifetime cap) | Marketed prominently |
| AIA | Standard | High cap | Marketed prominently |
| Tokio Marine Anshin lineage | Standard | High cap | Marketed prominently |
| Sompo Himawari | Standard | High cap | Marketed prominently |
| MS Aioi | Standard | High cap | Marketed prominently |
| Manulife / Prudential | Standard | High cap | Bundled with protection plan |
| Life big-4 mutuals | Standard | High cap | Rider attached to whole-life base |
| Foreign-currency medical | Standard | Foreign-currency-denominated cap | Foreign-currency policy lens |
| Online direct (yen term) | Standard rider | Yen cap | Marketed as core differentiator |

### Foreign-currency medical / annuity overlay

The following table is scoped to public primary sources (fsa.go.jp, seiho.or.jp, aflac.co.jp). It restates licence / structure / product boundaries from those materials and does not invent market share, ranking, or unstated numerical claims. ^[source:fsa.go.jp; seiho.or.jp; aflac.co.jp; aia.co.jp]

| Carrier set | Foreign-currency medical / cancer product presence | Notes |
|---|---|---|
| Aflac | Limited | Primarily yen-denominated |
| AIA | Selective | USD whole-life with medical rider available |
| Tokio Marine Anshin lineage | Selective | Foreign-currency whole-life with rider available |
| Sompo Himawari | Selective | Foreign-currency whole-life with rider available |
| MS Aioi | Selective | Foreign-currency whole-life with rider available |
| Manulife / Prudential | Significant | USD-denominated whole-life with medical rider, bancassurance distribution route |
| Life big-4 mutuals | Selective | Sold via bancassurance affiliates ([[life-insurers/dai-ichi-frontier-life|Dai-ichi Frontier Life]], [[life-insurers/ms-primary-life|MS Primary Life]]) more than core mutual |
| Kampo Life | Limited | Product-approval constraint |

### Conceptual market share signal

The following table is scoped to public primary sources (fsa.go.jp, seiho.or.jp, aflac.co.jp). It restates licence / structure / product boundaries from those materials and does not invent market share, ranking, or unstated numerical claims. ^[source:fsa.go.jp; seiho.or.jp; aflac.co.jp; aia.co.jp]

| Segment | Largest share (conceptual) | Other significant carriers |
|---|---|---|
| New cancer-insurance market | Aflac (~70% historically) | Sompo Himawari, AIA, MS Aioi, Tokio Marine Anshin lineage |
| New medical-insurance market | Aflac / Sompo Himawari / Orix (outside this matrix) compete | Tokio Marine Anshin lineage, MS Aioi, AIA, life big-4 |
| Whole-life with medical rider | Life big-4 mutuals dominant by reserves | Foreign affiliates strong on new sales |
| Term + medical rider | Spread across life big-4 + foreign affiliates | Lifeplanner / FA channel strong |
| Internet direct medical / cancer | [[life-insurers/lifenet|Lifenet]], [[life-insurers/sbi-life|SBI Life]] grow share | Selective offerings from incumbents |
| Bancassurance medical / cancer | Aflac (Japan Post Bank), foreign-currency annuity carriers | Major channel for foreign-currency medical bundle |

## Historical and structural context

The current Japanese medical-insurance structure reflects several decades of product and regulatory evolution:

- **1974 Aflac cancer-insurance entry** introduced specialty cancer insurance to the Japanese market and built the segment. Aflac's distribution combined corporate / employer group sales and agency.
- **1995 Insurance Business Act revision** modernised the licensing regime and laid the foundation for foreign-affiliate expansion in the protection / medical specialty.
- **1996–2001 third-sector liberalisation** opened the medical / cancer / nursing specialty to foreign affiliates and to non-life-group life subsidiaries on a level playing field. The third sector (第三分野) is the regulatory category for medical / cancer / nursing products that sit between life (第一分野) and non-life (第二分野).
- **2001 onward Japan Post Bank distribution alliance** scaled Aflac cancer-insurance reach through the Japan Post Bank counter network.
- **Late 2000s onward 先進医療 rider standardisation** made the advanced-medical-treatment rider an industry-standard add-on with high actual-cost caps.
- **2010s short-payment-period (短期払) product wave** offered 60-payment / 65-payment level-premium structures that finish premium payment before retirement, with whole-life cover continuing.
- **2010s foreign-currency-bundle expansion** combined foreign-currency whole-life with medical riders through bancassurance, distributed by [[life-insurers/dai-ichi-frontier-life|Dai-ichi Frontier Life]], [[life-insurers/ms-primary-life|MS Primary Life]], Manulife, and similar.
- **2015 onward 引受基準緩和 (limited-underwriting) expansion** opened medical / cancer cover to older / mildly-impaired applicants who would have been declined under standard underwriting.
- **2020s wellness-linked products** ([[life-insurers/sumitomo-life|Sumitomo Life]] Vitality and similar) link premium discounts to health behaviour and biometric data.
- **2025 ESR rollout** under the FSA economic-value-based solvency regime affects the capital treatment of medical / cancer liability cash flows for all FSA-perimeter carriers — see [[insurance/economic-value-based-solvency|economic-value-based solvency]] and [[insurance/esr-economic-value-solvency|ESR]].

## Decision use

Use this matrix when reading the Japanese medical-insurance competitive set against each other rather than against the broader life industry. Practical questions:

- **Cancer specialty vs medical bundle.** Aflac dominates stand-alone cancer; multiple carriers compete on medical. A household buying cancer-specific cover faces a different competitive set than one buying general medical.
- **Surrender-value design.** Modern medical / cancer products are designed as pure protection with no significant surrender value. Older policies may have surrender value built in. The choice affects premium curve and tax treatment.
- **Whole-life vs short-payment.** Short-payment-period products finish premium payment before retirement at the cost of higher early-year premiums. The 解約返戻金 (surrender value) trajectory and the protection-cost economics differ.
- **Foreign-currency medical bundle.** USD-denominated whole-life with medical rider transfers FX risk to the policyholder but offers higher cash-value-projection grammar. The bancassurance distribution route is the principal channel.
- **Channel suitability.** Tied sales force is the dominant channel for life-big-4 medical riders; agency / shop is the dominant channel for foreign-affiliate stand-alone medical / cancer; bancassurance dominates foreign-currency bundle; direct online is the [[life-insurers/lifenet|Lifenet]] / [[life-insurers/sbi-life|SBI Life]] lane.
- **Kyosai-perimeter alternative.** Many households hold both FSA-perimeter medical / cancer cover and kyosai medical rider (JA共済 / Zenrosai / Kenmin-kyosai / COOP共済). See [[insurance/japan-kyosai-vs-fsa-insurance-perimeter-matrix|the kyosai vs FSA perimeter matrix]] for the cooperative-perimeter overlay.
- **MHLW national-health-insurance interaction.** Japanese medical insurance products sit on top of the [[insurance/medical-cancer-insurance-product-economics|public health insurance system]] (公的医療保険) where MHLW caps out-of-pocket via the 高額療養費 system. The supplementary-cover product design assumes this base layer.

## Boundary cases / caveats

- **Numbers are conceptual.** Market shares (notably Aflac's ~70% cancer share), premium rates, benefit caps, and rider availability change with each product cycle and disclosure period. Sources are FSA, Seiho industry publications, each carrier's product brochures and integrated / disclosure documents, and MHLW publications on public health insurance.
- **Aflac cancer share.** The ~70% figure is widely cited industry shorthand for new cancer-insurance market share and has held over many years. Specific recent vintages should be confirmed against Aflac's disclosure and Seiho industry data.
- **Carrier-naming history.** Several carriers have renamed or merged (Anshin Seimei → Tokio Marine & Nichido Life lineage; Sompo Japan Nipponkoa Himawari Life → Sompo Himawari Life; AIG Star Life → AIA Japan lineage; Sumitomo Life Vitality is a wellness-linked product line, not a separate carrier). The matrix uses the current entity name.
- **Third-sector (第三分野).** Medical, cancer, and nursing products sit in the third sector for regulatory purposes — between life (第一分野) and non-life (第二分野). All FSA-perimeter life carriers (and non-life carriers via life subsidiaries) participate.
- **Foreign-currency products.** Foreign-currency whole-life with medical rider transfers FX risk to the policyholder. Conduct rules require dedicated suitability and explanation for these products, especially for elderly customers. See [[insurance/bancassurance-economics-japan|bancassurance economics Japan]].
- **Online-direct contrast.** [[life-insurers/lifenet|Lifenet]] and [[life-insurers/sbi-life|SBI Life]] do not appear as primary competitors in the cancer-specialty matrix above but are growing players in pure medical / cancer specialty at lower premium points. See [[insurance/internet-life-insurance-business-model|the internet life model]].
- **Wellness-linked products.** Vitality and similar wellness-linked product menus reward behaviour with premium discounts. The structural feature affects long-run pricing and persistency but does not change the product-line classification.
- **Surrender value and tax.** 解約返戻金 (surrender value) on medical / cancer products is generally suppressed by design; the cash-value tax treatment on whole-life base policies follows the standard income-tax code.
- **Public health insurance base.** Japanese supplementary medical products assume the public-health-insurance base. Changes in 高額療養費 (high-cost medical treatment) cap rules can affect supplementary-product economics.
- **Kampo Life product menu.** Subject to special-law approval constraints. Read [[insurance/kampo-japan-post-insurance|the Kampo entry]] separately.

## Related

- [[insurance/INDEX]]
- [[insurance/medical-cancer-insurance-product-economics]]
- [[insurance/japan-life-insurance-big-four]]
- [[insurance/japan-life-big-four-overlay-comparison-matrix]]
- [[insurance/foreign-life-affiliate-japan-positioning]]
- [[insurance/internet-life-insurance-business-model]]
- [[insurance/life-insurance-channel-mix]]
- [[insurance/insurance-agency-and-brokerage-japan]]
- [[insurance/bancassurance-economics-japan]]
- [[insurance/japan-bancassurance-distribution-overlay-matrix]]
- [[insurance/japan-kyosai-vs-fsa-insurance-perimeter-matrix]]
- [[insurance/sony-life-group-life-operating-model]]
- [[insurance/economic-value-based-solvency]]
- [[insurance/esr-economic-value-solvency]]
- [[insurance/kampo-japan-post-insurance]]
- [[life-insurers/aflac-japan]]
- [[life-insurers/aia-life-japan]]
- [[life-insurers/manulife-japan]]
- [[life-insurers/prudential-japan]]
- [[life-insurers/axa-japan]]
- [[life-insurers/tokio-marine-nichido-life]]
- [[life-insurers/sompo-himawari-life]]
- [[life-insurers/mitsui-sumitomo-aioi-life]]
- [[life-insurers/nippon-life]]
- [[life-insurers/dai-ichi-life]]
- [[life-insurers/sumitomo-life]]
- [[life-insurers/meiji-yasuda]]
- [[life-insurers/sony-life]]
- [[life-insurers/lifenet]]
- [[life-insurers/sbi-life]]
- [[life-insurers/kampo-life]]
- [[INDEX|FinWiki index]]

## Sources

- FSA: [Regulated entities and licensed insurers](https://www.fsa.go.jp/en/regulated/).
- Seiho: [Life Insurance Association member-company list](https://www.seiho.or.jp/english/about/companies/).
- MHLW: [Public health insurance system (公的医療保険)](https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/iryouhoken_iryouhoken01/index.html).
- Aflac Japan: [corporate information](https://www.aflac.co.jp/corp/).
- AIA Japan: [corporate information](https://www.aia.co.jp/ja/about-aia.html).
- Tokio Marine & Nichido Life: corporate / product disclosure.
- Sompo Himawari Life: [corporate information](https://www.himawari-life.co.jp/company/).
- Mitsui Sumitomo Insurance: [corporate information](https://www.ms-ins.com/company/).
- Aioi Nissay Dowa Insurance: [corporate information](https://www.aioinissaydowa.co.jp/corporate/).
- Manulife Japan: [corporate information](https://www.manulife.co.jp/about_us/).
- Prudential Japan: [corporate information](https://www.prudential.co.jp/about/).
- Nippon Life: [global IR / integrated reports](https://www.nissay.co.jp/global/).
- Dai-ichi Life Holdings: [IR](https://www.dai-ichi-life-hd.com/en/).
- Sumitomo Life: [IR / integrated reports](https://www.sumitomolife.co.jp/english/).